Готові списки джерел за темами / GBM Patients

Добірка наукової літератури з теми "GBM Patients"

Автор: Grafiati
Опубліковано: 6 вересня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Зміст

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "GBM Patients".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "GBM Patients"

1

Connelly, Jennifer, Kathleen Schmainda, Mona Al-Gizawiy, Fernando Santos-Pinhero, and Christopher Chitambar. "TIPS-03 A PHASE 1 STUDY OF GALLIUM MALTOLATE (GAM) IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)." Neuro-Oncology Advances 5, Supplement_3 (August 1, 2023): iii34. http://dx.doi.org/10.1093/noajnl/vdad070.134.

Повний текст джерела
Анотація:
Abstract Glioblastoma remains the most aggressive malignant brain tumor with universally poor prognosis. New treatments are needed which target novelpathways. GBM cells have significantly greater requirements for iron and display markedly higher levels of transferrin receptors for iron uptake and ferritin for iron storage than surrounding normal astrocytes. The increased intracellular iron pool drives GBM activity. Previously, we showed that since gallium shares certain chemical properties with iron, it can inhibit malignant cell growth by disrupting tumor iron homeostasis. Recently, we reported that GaM is cytotoxic to GBM cell lines and stem cells but not to microvascular endothelial cells. In rodent orthotopically implanted human GBM xenografts, orally administered GaM reduced tumor volume and prolonged animal survival. These preclinical studies form the basis for our Phase 1 study which evaluates GaM in patients with recurrent GBM. The trial will follow a 3 + 3 phase 1 dose escalation design. Three to six patients at each dose level will receive GaM 500 mg/d, 1000 mg/d, or 1500 mg/day for a minimum of two 28-day cycles. Patients age >= 18 years with histologically confirmed GBM or molecular GBM with recurrent measurable disease are eligible. In the absence of measurable disease, pathologic confirmation of recurrence is required. Primary objectives are to determine a maximum-tolerated dose and recommended Phase 2 dose. Safety/tolerability will be assessed. Secondary objectives include disease assessments and evaluation of PFS and OS. Correlative studies planned are sequential blood levels of gallium, iron, Tf, ferritin, and hepcidin. Available tumor tissues will be examined for the expression iron biomarkers by immunochemistry. The study is currently enrolling. Patients will receive study drug until disease progression, unacceptable adverse events, patient withdrawal, or death. To date, 5 patients received GaM 500 mg/d without DLT and 4 patients started GaM 1000 mg/d.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Wu, Mengwan, Ying Shi, Luyi Zhu, Luoyi Chen, Xinchen Zhao, and Chuan Xu. "Macrophages in Glioblastoma Development and Therapy: A Double-Edged Sword." Life 12, no. 8 (August 12, 2022): 1225. http://dx.doi.org/10.3390/life12081225.

Повний текст джерела
Анотація:
Glioblastoma (GBM) is one of the leading lethal tumors, featuring aggressive malignancy and poor outcome to current standard temozolomide (TMZ) or radio-based therapy. Developing immunotherapies, especially immune checkpoint inhibitors, have improved patient outcomes in other solid tumors but remain fatigued in GBM patients. Emerging evidence has shown that GBM-associated macrophages (GAMs), comprising brain-resident microglia and bone marrow-derived macrophages, act critically in boosting tumor progression, altering drug resistance, and establishing an immunosuppressive environment. Based on its crucial role, evaluations of the safety and efficacy of GAM-targeted therapy are ongoing, with promising (pre)clinical evidence updated. In this review, we summarized updated literature related to GAM nature, the interplay between GAMs and GBM cells, and GAM-targeted therapeutic strategies.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Bergallo, Massimiliano, Cristina Costa, Stefano Gambarino, Alessandra Tornicelli, Sara Astegiano, Maria Elena Terlizzi, Paolo Solidoro, and Rossana Cavallo. "Human cytomegalovirus glycoprotein B genotyping from bronchoalveolar lavage specimens." Canadian Journal of Microbiology 57, no. 4 (April 2011): 273–77. http://dx.doi.org/10.1139/w11-014.

Повний текст джерела
Анотація:
The genes encoding glycoprotein complexes of human cytomegalovirus are often polymorphic; in particular, glycoprotein B (gB), which is essential for both in vivo and in vitro replication, is encoded by the highly polymorphic gene UL55. In this study, the distribution of gB genotypes was investigated in 44 bronchoalveolar lavage specimens from adult patients positive for human cytomegalovirus DNA by a multiplex nested fast PCR able to amplify 5 gB genotypes (gB1–gB5). The distribution of gB genotypes was as follows: 12 (27.3%) gB1, 11 (25%) gB2, 9 (20.4%) gB3, 4 (9.1%) gB4, 0 gB5, and 8 (18.2%) mixed genotypes. No difference in prevalence was found in relation to clinical features, including immunological status, non-transplant or transplant condition, and type of transplanted organ, or in follow-up specimens; while gB4 and gB3 were shown to be significantly more prevalent in patients with respiratory insufficiency, and gB4 and gB2 in those with pneumonia. The prevalence of gB genotypes in the lower respiratory tract was similar to that previously reported using other specimen types and patients, with gB1 found to be the most prevalent. The association of gB genotypes with specific clinical features should be further investigated.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Nelson, James S. "Alzheimer Pathology in Elderly Patients With Glioblastoma Multiforme." Archives of Pathology & Laboratory Medicine 126, no. 12 (December 1, 2002): 1515–17. http://dx.doi.org/10.5858/2002-126-1515-apiepw.

Повний текст джерела
Анотація:
Abstract Context.—Alzheimer disease (AD) and glioblastoma multiforme (GBM) have similar peak, age-specific incidence rates; however, to my knowledge, only 1 case of GBM associated with AD has been reported to date. The frequency of AD pathology, including neuritic plaques, diffuse plaques, neurofibrillary tangles, and cerebral amyloid angiopathy in patients with GBM is unknown. Studies of cancer occurrence in patients with AD are contradictory, with frequencies reported as equal to and as less than that in the general population. The GBM/AD nonconcordance may reflect underreporting of AD pathology or other factors. Objective.—To compare the frequency and extent of neocortical AD pathology in autopsy cases involving patients aged 60 to 82 years, both with and without GBM. Design.—Case-control study. Setting.—Pathology department of a university hospital. Patients.—Thirty-six autopsy cases of GBM patients aged 60 to 82 years; 54 cases of patients in the same age group without GBM or other primary brain tumors. Methods.—Examination of tumor sections for GBM and of neocortical sections for AD pathology according to Consortium to Establish a Registry for Alzheimer Disease (CERAD) guidelines. Results.—Glioblastoma multiforme was confirmed in all tumor cases. Alzheimer disease pathology was present in 42% of cases with GBM and in 48% of cases without GBM; 28% of GBM cases had CERAD age-related plaque scores indicative or suggestive of AD; 43% of cases without GBM had CERAD age-related plaque scores indicative or suggestive of AD. Conclusions.—Alzheimer disease pathology was underreported in both GBM and non-GBM patients. The influence of neurodegenerative processes on GBM symptoms and therapy in elderly patients requires further study.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Botturi, M., L. Fariselli, I. Milanesi, D. Asnaghi, S. Bracelli, G. Broggi, and D. Zanni. "GBM: A review of 118 patients." European Journal of Cancer 29 (January 1993): S193. http://dx.doi.org/10.1016/0959-8049(93)91700-u.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Nakamura, Masaya, Osahiko Tsuji, Kanehiro Fujiyoshi, Kota Watanabe, Takashi Tsuji, Ken Ishii, Morio Matsumoto, Yoshiaki Toyama, and Kazuhiro Chiba. "Cordotomy for patients with thoracic malignant astrocytoma." Journal of Neurosurgery: Spine 13, no. 4 (October 2010): 418–23. http://dx.doi.org/10.3171/2010.4.spine09901.

Повний текст джерела
Анотація:
Object The optimal management of malignant astrocytomas remains controversial, and the prognosis of these lesions has been dismal regardless of the administered treatment. In this study the authors investigated the surgical outcomes of cordotomy in patients with thoracic malignant astrocytomas to determine the effectiveness of this procedure. Methods Cordotomy was performed in 5 patients with glioblastoma multiforme (GBM) and 2 with anaplastic astrocytoma (AA). A Kaplan-Meier survival analysis was performed, and the associations of the resection level with survival and postoperative complications were retrospectively examined. Results Cordotomy was performed in a single stage in 2 patients with GBM and in 2 stages in 3 patients with GBM and 2 patients with AA. In the 2 patients with GBM, cordotomy was performed 2 and 3 weeks after a partial tumor resection. In the 2 patients with AA, the initial treatment consisted of partial tumor resection and subtotal resection combined with radiotherapy, and rostral tumor growth and progressive paralysis necessitated cordotomy 2 and 28 months later. One patient with a secondary GBM underwent cordotomy; the GBM developed 1 year after subtotal resection and radiotherapy for a WHO Grade II astrocytoma. Four patients died 4, 5, 24, and 42 months after the initial operation due to CSF dissemination, and 3 patients (2 with GBM and 1 with AA) remain alive (16, 39, and 71 months). No metastasis to any other organs was noted. Conclusions One-stage cordotomy should be indicated for patients with thoracic GBM or AA presenting with complete paraplegia preoperatively. In patients with thoracic GBM, even if paralysis is incomplete, cordotomy should be performed before the tumor disseminates through the CSF. Radical resection should be attempted in patients with AA and incomplete paralysis. If the tumor persists, radiotherapy and chemotherapy are indicated, and cordotomy should be reserved for lesions growing progressively after such second-line treatments.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Larionova, T. D., T. F. Kovalenko, M. I. Shakhparonov, and M. S. Pavlyukov. "The Prognostic Significance of Spliceosomal Proteins for Patients with Glioblastoma." Doklady Biochemistry and Biophysics 503, no. 1 (April 2022): 71–75. http://dx.doi.org/10.1134/s1607672922020090.

Повний текст джерела
Анотація:
Abstract Glioblastoma (GBM) is considered one of the most aggressive human cancers. Earlier, our group have demonstrated that alternative RNA splicing plays an important role in the regulation of the GBM phenotype. To continue this study, we analyzed the type of RNA splicing and the expression levels of the spliceosomal genes in a large number of tumor tissue samples and patient-derived GBM sphere lines. We demonstrated that the expression level of splicing factors allows dividing GBM patients into groups with different survival prognosis and also reflects the phenotype of the tumor. In addition, we identified the alternative splicing events that may regulate the GBM phenotype. Finally, we for the first time compared the expression profiles of the spliceosomal genes in different regions of the same tumor and identified splicing factors whose expression most significantly correlates with GBM patients’ survival. Aforementioned data emphasize the important role of pre-mRNA splicing in GBM progression.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Takeuchi, Yasuo, Emiko Takeuchi, and Kouju Kamata. "A Possible Clue for the Production of Anti-Glomerular Basement Membrane Antibody Associated with Ureteral Obstruction and Hydronephrosis." Case Reports in Nephrology and Dialysis 5, no. 1 (March 31, 2015): 87–95. http://dx.doi.org/10.1159/000381396.

Повний текст джерела
Анотація:
Background: Anti-glomerular basement membrane (anti-GBM) antibody-mediated glomerulonephritis (anti-GBM GN) is an autoimmune disease with rapidly progressive glomerulonephritis. Based on a case report of anti-GBM GN following hydronephrosis, we hypothesized that hydronephrosis may act as a trigger for the development of anti-GBM antibodies. Patients and Methods: We evaluated 11 patients who were diagnosed with hydronephrosis. It was measured with serum anti-GBM antibody. These patients' medical histories as well as risk factors for the development of anti-GBM antibodies and causes of hydronephrosis were reviewed. Renal function and hematuria were also considered. The serum anti-GBM antibody was measured with enzyme-linked immunosorbent assays (ELISA) or chemiluminescent enzyme immunoassays (CLEIA). Histopathological findings of renal biopsy specimens were also evaluated. Results: No patient had a medical history of renal disease. Five patients had a history of smoking. Ten of the 11 patients had renal dysfunction as evidenced by serum creatinine levels of 0.85-13.8 mg/dl, while 8 patients had RBCs in their urinary sediment at the time of diagnosis for hydronephrosis. Two of the patients assessed by ELISA and CLEIA were positive for anti-GBM antibodies. In 1 of these 3 patients, anti-GBM antibodies and renal dysfunction improved upon treatment for hydronephrosis. Another of the 3 patients developed anti-GBM GN, but anti-GBM antibodies and renal dysfunction improved dramatically upon treatment. In the 3rd patient without improved hydronephrosis, anti-GBM antibodies and renal dysfunction remained unchanged. Conclusion: Our results provide insights into the development of anti-GBM antibodies in patients with ureteral obstruction and hydronephrosis.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Chabot, Peter, Dominique Fontaine, Carmen del Genio, Yujia Shentu, and Arti Gaur. "BIOM-14. SYSTEMIC BIOMARKERS OF TUMOR BURDEN IN GLIOBLASTOMA PATIENTS." Neuro-Oncology 24, Supplement_7 (November 1, 2022): vii7. http://dx.doi.org/10.1093/neuonc/noac209.024.

Повний текст джерела
Анотація:
Abstract Glioblastomas (GBM) are Grade IV gliomas that are highly aggressive, lethal primary brain tumors. They are extremely heterogenous tumors both at a cellular and molecular level, harboring diverse oncogenes and mutated tumor suppressor genes with both inter- and intra-tumor variability in expression patterns. Currently, the presence of GBM cannot be predicted and they are diagnosed post-surgical resection by histologic evaluation of tumor tissue. There is an urgent, unmet need for the discovery of GBM-specific biomarkers that could precisely predict and monitor the presence of tumors in GBM patients. Over the last seven years we have carried out a prospective, multi-center, clinical study to longitudinally analyze tumor and plasma samples from GBM patients. We have characterized expression levels of microRNAs, mRNAs and proteins isolated from plasma samples collected from GBM patients throughout their treatment and compared these data to clinical and pathological reports for each patient. Our research has identified a set of systemic microRNAs and their targets that can be correlated to tumor burden in GBM patients. Data will be presented to demonstrate how specific sets of molecular markers and secreted proteins can track disease in GBM patients. This study provides insights into how systemically expressed biomarkers in GBM patients can be used in the development of methods for the precise assessment of disease progression and treatment efficacy while being minimally invasive and cost-effective. Combining clinicopathological findings and biomarker profiling will predict treatment outcomes and provide oncologists precise readouts for tumor burden and response to treatment. Furthermore, this research will also provide critically needed criteria for rigorous monitoring of efficacy of all new therapeutic trials for GBM.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Bacha, Jeffrey A., Anne Steino, Richard Stephen Schwartz, John Langlands, Sarath Kanekal, Lorena Lopez, Barbara Jane O'Brien, Zhongping Chen, Marta Penas-Prado, and Dennis Brown. "Clinical trials of VAL-083 in patients with chemo-resistant glioblastoma." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): TPS2082. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.tps2082.

Повний текст джерела
Анотація:
TPS2082 Background: Glioblastoma (GBM) is the most common and aggressive primary brain cancer. Current standard of care includes surgery, radiation and treatment with temozolomide (TMZ), however nearly all tumors recur and the prognosis for recurrent GBM is dismal. Most GBM tumors have unmethylated promoter status for O6-methylguanine-DNA-methyltransferase (MGMT); a validated biomarker for TMZ-resistance. Second-line treatment with anti-angiogenic agent bevacizumab has not improved overall survival (OS) and 5-year survival is less than 3%. Dianhydrogalactitol (VAL-083) is a bi-functional alkylating agent targeting N7-Guanine and inducing interstrand DNA cross-links, double-strand breaks and cell death in GBM cell lines and GBM cancer stem cells, independent of MGMT status in vitro. VAL-083 readily crosses the blood-brain barrier and accumulates in brain tumor tissue. Our recent phase I/II clinical trial in recurrent GBM patients failing both TMZ and bevacizumab, suggested that VAL-083 offers clinically meaningful survival benefits for patients with recurrent GBM and pinpointed a new dosing regimen (40 mg/m2/d on days 1,2,3 of a 21-day cycle) which was well-tolerated and was selected for study in subsequent GBM trials. Methods: These trials include i) an ongoing single-arm, biomarker driven, Phase 2 study to determine if VAL-083 treatment of MGMT-unmethylated adult GBM patients at first recurrence/progression, prior to bevacizumab improves overall survival at 9 months, compared to historical control with lomustine (clinicaltrials.gov identifier: NCT02717962). ii) A pivotal Phase 3 study in recurrent GBM after failing both TMZ and bevacizumab. The control arm will consist of a limited number of salvage chemotherapies currently used in bevacizumab-failed GBM. If successful, this study will serve as the basis for a New Drug Application (NDA) submission for VAL-083. iii) A single arm, biomarker driven, Phase 2 study to confirm the tolerability and efficacy of VAL-083 in combination with radiotherapy in newly diagnosed MGMT-unmethylated GBM patients whose tumors are known to express high MGMT levels. The results of these studies may support a new treatment paradigm in chemotherapeutic regimens for the treatment of GBM. Clinical trial information: NCT02717962.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "GBM Patients"

1

De, Gzell Cecelia Elizabeth. "OPTIMISING OUTCOMES IN PATIENTS WITH GLIOBLASTOMA RECEIVING RADIOTHERAPY." Thesis, The University of Sydney, 2016. http://hdl.handle.net/2123/16549.

Повний текст джерела
Анотація:
More than 1,400 new cases of malignant brain tumours are diagnosed each year in Australia. Glioblastoma, or GBM, remains the most common primary brain tumour in adults and the most devastating. The median age at diagnosis is 61 years and the median survival from diagnosis is only approximately 14 months. The aim of the work presented in this thesis is to optimise radiotherapy protocols in patients with glioblastoma to improve patient outcomes by targeting particular time points along the patients’ treatment journey. After describing the disease and epidemiology of GBM in Chapter 1, Chapter 2 explores the evolution of RT technique in treating this disease throughout the ages. In this disease patients >65 years are considered “elderly” and have a poorer prognosis compared with their younger cohorts. They also represent the majority of patients with GBM as the incidence for this tumour peaks in the sixth and seventh decades. There is currently no internationally accepted standard of care for treating this group. Chapter 3 analyses different RT protocols in this cohort of patients. The remaining chapters examine different aspects of the patient’s post-RT journey. Chapter 4 analyses the phenomenon of pseudoprogression (PsP), a radiological diagnosis of an increase in abnormality on post-RT magnetic resonance imaging (MRI) scan which subsequently improves over time with no change in treatment. This phenomenon is poorly understood and the pathological characteristics are explored. Directly expanding from the work on pseudoprogression, Chapter 5 introduces novel volumetric techniques to analyse post-RT MRI changes and explores whether these impact patients’ survival. Chapter 6 deals with the survivorship issue of a patient’s ability to return to work following RT. As patients are living longer with this disease, and a greater proportion are remaining functionally well until late in the course of the disease, more patients are being offered re-irradiation as part of their salvage treatment. Chapter 7 analyses the evolving role of re-irradiation. RT in addition to surgery remains the cornerstone of treatment of GBM. With ongoing improvements in the technical delivery of RT we expect there to be clinical benefit for patients with reduced short-and late toxicity, if not an improvement in survival. This thesis explores different aspects of the patients’ treatment journey on topics that have previously been poorly understood or novel areas of research.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

RANCATI, SILVIA. "A nanoformulated 11-miRNA pool synergistically modulates GBM cells invasion and in vivo growth." Doctoral thesis, Università degli studi di Genova, 2021. http://hdl.handle.net/11567/1045591.

Повний текст джерела
Анотація:
Glioblastoma (GBM) is the most common and fatal cancer of the adult brain, with an annual incidence rate of 2-3 per 100 000 (US) and a median survival time around 14 months. GBM is characterized by an infiltrative growth pattern that makes its complete surgical resection arduous. Moreover, the presence of a therapy-refractory cancer stem cell (CSC) component has been linked to the unavoidable insurgence of tumor recurrence experienced by patients. The failure of current therapeutic standards at completely eradicate this tumor fuels an intense research effort for the identification and development of new therapeutic strategies. To achieve the cure of this malignancy, while preventing its recurrence, the ideal treatment should target both the invasive behavior of GBM and the cancer stem cell population (the latter with so called “differentiation therapy”). MicroRNAs (endogenous small non-coding RNAs regulating the gene expression at the post transcriptional level) show dysregulated expression in tumors compared to healthy tissues and are involved in several of the “hallmarks of cancer”: hence, they have raised attention for their therapeutic potential. The development of miRNA-based therapies is an expanding field of research: in recent years several formulations entered into clinical trials for treating various malignancies, but none for brain cancers, indicating room for improvement. The functional synergism of multiple, different miRNA, also known as cooperation or convergence, has been proposed as one of the mechanisms that confer robustness to miRNA-mediated regulation of large number of genes, allowing these tiny RNAs to orchestrate essential cellular pathways. MiRNA-based therapies for cancer could benefit from the functional synergism of different miRNAs, especially considering the high intra-tumoral heterogeneity and the number of redundant and compensatory mechanisms of therapy-resistance that characterize refractory tumors as GBM, that are unlikely to be effectively targeted by a single molecule. Our lab previously identified a “pool” of 11 miRNAs necessary and sufficient to sustain neuronal differentiation of adult neural stem cells in mice by the synergic repression of targets involved in cell morphogenesis and neuron differentiation (Pons-Espinal et al., 2017). This pool is conserved in human and dysregulated in GBM. The molecular and cellular similarities between GBM stem cells (GSC) and neural stem cells (NSC) led to the hypothesis to employ the 11-miRNA pool in GBM, with the originary idea to target the GSC component of this tumor with potential benefit. Building on the combinatorial nature of the miRNA pathway and on previous results by the host lab, indicating an essential role of the miRNA pool to control NSCs differentiation, the overarching goal of my PhD project was to deploy the 11-miRNA pool in an anticancer therapy against GBM, to test its tumor-suppressive potential and to identify the molecular mechanisms underlying its therapeutic effects. Main results achieved by this work are: I. The identification of a fundamentally anti-invasive role of the 11 miRNAs, achieved in GBM by synergistic regulation of a wide network of proteins involved in cell-adhesion, cytoskeleton reorganization and extracellular matrix remodeling. Importantly, many of the proteins downregulated by the pool are relevant in GBM pathogenesis and thereby possible targets for future development of conventional drug-based therapies. II. The development of a delivery strategy that possesses a realistic translational potential, taking the example from clinically approved lipid nanoparticles formulations, considered a leading-edge vector for small RNAs delivery. III. The demonstration that the functional synergism of the 11-miRNA pool, enhanced in vivo by nano-delivery, is an effective strategy to slow-down the in vivo growth of an aggressive model of human GBM.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Pavliš, Jaroslav. "Přenos pacientských informací pomoci GSM." Master's thesis, Vysoké učení technické v Brně. Fakulta elektrotechniky a komunikačních technologií, 2008. http://www.nusl.cz/ntk/nusl-217737.

Повний текст джерела
Анотація:
This diploma thesis is concerned with possibilities of patient data transfer from a pacemaker or implantable cardioverter-defibrillator to physician over GSM. Theoretical part describes options of data transfer in GSM networks, data appropriate for sending and a structure of message is proposed. A device, that is able to send medical data in a form of SMS messages is designed and constructed. The device uses a Freescale MC68HC908GP32 microcontroller, character display with a Hitachi HD44780 controller and a cell phone Sony CMD-J70. The program for microcontroller is written in assembler for HC08. For tabular view of received messages, an application software for PC was created.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Kober, Sylvia Deborah geb Pflederer [Verfasser]. "Parkinson’s disease patients with heterozygous GBA-mutation : longitudinal phenotyping of motor and non-motor symptoms – more rapid progression compared to Parkinson’s disease patients without GBA-mutation / Sylvia Deborah geb. Pflederer Kober." Tübingen : Universitätsbibliothek Tübingen, 2021. http://d-nb.info/1226756417/34.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Galper, Jasmin. "Inflammatory and lipid markers in clinical and pre-clinical Parkinson’s disease patients." Thesis, The University of Sydney, 2021. https://hdl.handle.net/2123/27967.

Повний текст джерела
Анотація:
Parkinson’s disease (PD) risk gene discoveries have implicated lipids and inflammation in pathology. However, most research to date has been protein-centric. Therefore, the extent of lipid involvement in PD and relationships between inflammatory and lipid pathways are unclear. Research into these areas may provide novel insights into PD pathology, therapeutic targets and biomarkers for an earlier diagnosis and monitoring disease progression in clinical trials. To investigate lipid dysregulation in PD and in mutation carriers of the PD risk gene LRRK2, untargeted mass spectrometry was performed using serum (N = 221) and cerebrospinal fluid (CSF, N = 88) from controls, pre-clinical and clinical PD LRRK2 G2019S carriers and sporadic PD patients. Findings were then validated in a second cohort (N = 315) using serum from the same groups. Significant lipid alterations were found in mutation carrier and PD patient serum and CSF. Altered lipids implicated sphingolipid metabolism and insulin signalling pathways in PD. Further, altered serum and CSF lipids correlated with cytokines involved in insulin/glucose signalling. Pre-clinical PD biofluid changes suggest that lipids are worthwhile candidates for longitudinal studies assessing whether baseline markers predict PD. Correlation analysis indicated that although serum lipids did not robustly associate with clinical severity, CSF lipids were associated. Finally, whether mutations in the lipid-related risk gene, GBA, affected inflammatory markers was assessed in plasma (N = 371) from clinical and pre-clinical GBA mutation carriers, sporadic PD patients and controls. Inflammatory markers were overall unchanged in GBA mutation carriers, suggesting these are not promising biomarker candidates. These findings strongly support a role for lipid dysregulation in PD. These results indicate that lipids are promising candidates to pursue for understanding PD aetiology, as well as potential novel biomarkers for genetic and sporadic PD.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Hurley, Samantha Jane. "The physico-chemical mechanisms underlying the physiological effects of non-starch polysaccharides: studies in ileostomy patients." Thesis, University of Sheffield, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.310783.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

RIBOLDI, GIULIETTA. "INTEGRATED GENOMIC ANALYSIS OF ISOLATED CD14+ MONOCYTES IN PATIENTS WITH GBA-RELATED PARKINSON¿S DISEASE." Doctoral thesis, Università degli Studi di Milano, 2021. http://hdl.handle.net/2434/827744.

Повний текст джерела
Анотація:
Background: Genetic mutations of the gene encoding for the beta- glucocerebrosidase (GCase), GBA gene, represent the major genetic risk factor for Parkinson’s disease (PD). The pathogenic mechanisms associated with these mutations and modifiers responsible for the reduced penetrance of this gene are not fully elucidated yet. However, the function of the GBA gene is at the crossroad between the endo-lysosomal pathway and the immune response, which are two main mechanisms involved in PD pathogenesis. Aim: With the present work we aim to characterize the clinical features of a population of patients with PD and healthy controls (CTRL) with and without mutations of the GBA gene and characterize the transcriptomic profiles of purified CD14+ monocytes in order to identify 1) pathogenic mechanisms associated with GBA- PD; 2) potential biomarkers for earlier detection of GBA mutation carriers who will phenoconvert to a disease status; 3) new therapeutic targets for precision medicine approaches. Material and methods: PD patients and CTRL were enrolled at the Fresco Institute (NYU Langone Health, NY) and Mount Sinai School of Medicine (NY). Demographic information, clinical and family history, as well as motor and non-motor symptoms of PD were collected. DNA and RNA from purified CD14+ monocytes, plasma and peripheral blood mononuclear cells (PBMC) were collected. Genotyping (Illumina Global Screening Array with custom Neurodegenerative disease panel) and RNAseq analysis (60M ribo- depleted, paired-end reads) was performed. Data were analyzed through integrative genomic analysis leveraging different computational methods (differential expression, nested interaction model, outlier detection and trans-eQTLs). Results: Statistical analysis comparing the clinical phenotypes of 19 PD/GBA+, 37 PD/GBA-, 37 CTRL/GBA-, 9 CTRL/GBA+ showed increased non-motor symptoms in CTRL/GBA+ and increased family history and cognitive impairment in the PD/GBA+ cohort. Integrative genomic analysis of a cohort of 56 PD/GBA-, 66 CTRL/GBA-, 23 PD/GBA+, and 13 CTRL/GBA+ identified a large number of differentially expressed genes and deregulated pathways in the PD/GBA+ compared to CTRL/GBA+ as well as PD/GBA- groups. In particular, PD/GBA+ showed deregulated alpha-synuclein-, amyloid- and aging-related processes compared to PD/GBA-. Compared to CTRL/GBA+, in manifesting carriers there was a deregulation of all the major pathogenic pathways previously associated with PD. Outliers and trans-eQTLs analysis confirmed a prominent involvement of lysosomal, membrane trafficking, and mitochondrial targets, identifying also additional related genes. Discussion: Clinical and demographic analysis of PD patients and CTRL with and without GBA mutations highlighted characteristic features in the PD/GBA+ and CTRL/GBA+ cohort. Genomic analysis of isolated CD14+ monocytes identified specific molecular targets and deregulated pathways that can help understanding the pathogenic mechanisms associated with GBA mutations in the context of PD.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Kihlgren, Mona. "Integrity promoting care of demented patients." Doctoral thesis, Umeå universitet, Institutionen för omvårdnad, 1992. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-100570.

Повний текст джерела
Анотація:
The purpose of the thesis was to investigate if integrity promoting care improves functions in demented patients over time. The Erikson (1982) theory of ”eight stages of man” was used as a basis for training of staff in a three-month intervention study (I-VI) at a nursing home ward. A collective living unit where staff had had support in the performance of the delivery of care was also evaluated and compared with a nursing home in a long-term study (VII). Patients, relatives, staff, and the environments were investigated. Cerebrospinal fluid concentrations of somatostatin increased, and reduction of distractability, anxiety and confusion was seen in the intervention group (I) in contrast to controls. In the collective living group (VII) EEG activities indicated a reduction of supposed dementia induced changes. Better motor and social ability, some improved intellectual ability, more alertness and reduced signs of depression were seen (I, II, VII). Patients expressed more autonomy (IV, VII) and initiatives (II-VII) and showed a lot of competence (V) in conversations. Five patients (V) showed patterns of behaviour which seemed to reflect life-long characteristics in spite of their severe dementia. The improvement in the patients' functions can be attributed to the physical environment and the integrity promoting care, since the medical treatment of the patients remained unchanged. In the thesis medical, psychological, and nursing sciences were connected in a complementary process. The results were congruent, and indicate that patients in the care of staff who had had training and support, declined less than controls.

S. 1-61: sammanfattning, s. 63-184: 7 uppsatser


digitalisering@umu
Стилі APA, Harvard, Vancouver, ISO та ін.
9

江寶盈 and Po-ying Kong. "Relationship between self-reflection and insight in early psychosis patients using guided illness model questionnaire (GIM) / y Kong Po Ying, Cathy." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/192950.

Повний текст джерела
Анотація:
Insight impairment is commonly reported in psychosis patients and such impairment leads to poor outcome and it also causes burden to the family and caregivers. It is as yet unclear what causes unawareness of illness therefore it is essential to find out the key element to form this fundamental correlation. Wiffen and David proposed that self-reflective processing may have similar cognitive mechanisms as theory of mind processing, but this does not imply that the processes cannot be affected independently. Lysaker et al. demonstrated that better meta-cognitive skills, such as the ability to think about one’s own thoughts were related to better insight in schizophrenia patients. An increasing number of studies suggest that patients lacking insight into their own illness, were fully capable of recognizing the illness and symptoms in other patients. This indicated that insight impairment only happened at the self-recognition level. The ability of integrating information from outside world to the self is seen as a factor in gaining insight, therefore self-reflection ability are commonly seen as key features of awareness of mental illness. Previous studies of chronic schizophrenia patients show that their ability to accept the biological model of their own psychotic symptoms, assessed with Guided Illness Model Questionnaire (GIM) questionnaire, has a positive association with their neuropsychological function and awareness of illness However, it has not been common to use GIM questionnaire in early stage psychosis patients. This study aims are (1) use Guided Illness Model Questionnaire (GIM) to assess the self-reflection ability of early stage psychosis patients (2) explore the relationship between self-reflection and insight (3) Cognitive functions, particular executive functions, will be evaluated with self-reflection ability and insight. Insight will be measured by scale to assess unawareness of mental disorder (SUMD). Results show self-reflection ability is related with insight impairment and executive function, especially processing speed and attention contributes to self-reflection ability and poor insight. Further investigation reveals that self-reflection ability acts as a mediator for poor insight. This study concludes that executive functioning is the basic-order process for gaining insight and self-reflection could act as higher-order process as mediator for provoking insight for psychosis patients.
published_or_final_version
Psychological Medicine
Master
Master of Psychological Medicine
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Toupin, Amanda. "Analyse de biomarqueurs au niveau cellulaire de patients atteints de la maladie de Fabry en utilisant la spectrométrie de masse en tandem." Mémoire, Université de Sherbrooke, 2017. http://hdl.handle.net/11143/11789.

Повний текст джерела
Анотація:
La maladie de Fabry est une maladie de surcharge lysosomale liée au chromosome X. Elle est causée par une mutation au niveau du gène GLA qui provoque un déficit de l’enzyme α-galactosidase A. Elle entraîne une accumulation de glycosphingolipides tels le globotriaosylcéramide (Gb3), le globotriaosylsphingosine (lyso-Gb3) et galabiosylcéramide (Ga2) ainsi que leurs isoformes/analogues respectifs au niveau des tissus et des liquides biologiques des patients. Les symptômes peuvent se présenter de manière très variable soit par de l’acroparesthésie, des troubles ophtalmologiques, des angiokératomes, des troubles cardiaques, rénaux ou encore neurologiques. Les connaissances au niveau physiopathologique de la maladie de Fabry sont à ce jour, toujours déficientes. Les biomarqueurs analysés ne permettent pas de prédire la sévérité et la progression de la maladie. Afin d’apporter des connaissances plus approfondies à ce niveau, l’objectif principal de cette étude était d’analyser les biomarqueurs au niveau cellulaire pour des patients atteints de la maladie. Les objectifs secondaires étaient: 1) de développer et de valider une méthode en spectrométrie de masse en tandem pour la quantification relative et simultanée de certains biomarqueurs susmentionnés dans les leucocytes, les lymphocytes B et les monocytes de patients Fabry et contrôles sains; 2) d’évaluer les biomarqueurs dans le total des leucocytes, les lymphocytes B, les monocytes, le plasma et l’urine chez les patients Fabry et les contrôles sains appariés selon le sexe et l’âge; et 3) d’établir des corrélations entre la quantité relative de ces biomarqueurs et le génotype des patients traités et non traités. Les résultats de cette étude démontrent qu’il n’y a pas de changements significatifs dans la distribution des groupes d’isoformes/analogues du Gb3 selon le type cellulaire pour les patients et les contrôles. La découverte d’isoformes/analogues méthylés du Gb3 suggère un processus de méthylation qui se produit directement au niveau des cellules sanguines et particulièrement pour les lymphocytes B et les monocytes. Des corrélations face à la quantité de biomarqueurs et le génotype ont été établies. Ces résultats pourraient permettre une meilleure compréhension des processus biochimiques reliés à l’accumulation du Gb3 dans les cellules sanguines.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "GBM Patients"

1

Group, Diagram, ed. Collins gem patience card games. Glasgow: HarperCollins, 1996.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Herbelin, Yehonathan. Gam ani hayiti sham: I was there. Modiʻin: Kineret, 2019.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Elʻazar, Mosheh ben Shelomoh. Sefer Maʻaneh rakh: Bo yevoʼar ekh yitnaheg ha-adam ... she-lo yikhʻos ṿeshe-lo yaḳpid ṿe-lo yitraʻem ... ṿe-gam ... ʻal ezeh ha-ofanim mutar li-kheʻos ... ṿe-gam yevoʼar ... kol darkhe ha-teshuvah she-mefuzarim ben ha-sefarim ... Bene Beraḳ: Sifre Or ha-ḥayim, 2000.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Health policy in Britain: The politics and organisation of the National Health Service. 2nd ed. Basingstoke: Macmillan, 1985.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Health policy in Britain: The politics and organisation of the National Health Service. 3rd ed. Houndmills, Basingstoke, Hampshire: Macmillan, 1992.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Health policy in Britain: The politics and organisation of the National Health Service. 3rd ed. Basingstoke: Macmillan, 1992.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Cui, Zhao, Neil Turner, and Ming-hui Zhao. Antiglomerular basement membrane disease. Edited by Neil Turner. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0073_update_001.

Повний текст джерела
Анотація:
Cyclophosphamide and plasma exchange are the standard of care in rapidly progressive glomerulonephritis or lung haemorrhage caused by antiglomerular basement membrane (anti-GBM) disease, and it is unusual to encounter patients at earlier stages. Steroids are universally used in addition. There is some evidence that plasma exchange may not be a critical part of treatment at an earlier stage. There is no more than anecdotal evidence for other therapies. Slower-onset therapies such as antibodies to B cells are rarely appropriate. If untreated, patients with severe anti-GBM disease will not recover renal function and are at risk of pulmonary haemorrhage. Evidence for the pathogenicity of circulating anti-GBM antibodies provides rationale for removal of circulating antibodies as rapidly as possible, whilst simultaneously inhibiting their synthesis. This was behind the introduction of the combination of plasma exchange with immunosuppressive therapy in mid 1970s, which revolutionized outcomes. Plasmapheresis aims to remove circulating pathogenic antibodies against GBM and possibly other mediators; cyclophosphamide prevents further synthesis of autoantibodies; and steroids act as anti-inflammatory agents to attenuate the glomerular inflammatory response initiated by anti-GBM antibodies. It is clear from experimental models and occasional observations in man that the anti-cell mediated effects of current therapies are important too. Outcomes vary, but in general patient survival is now good, while renal survival remains poor, in many series less than 50% at 1 year. Treatment is toxic and after an early peak in deaths due to pulmonary haemorrhage, secondary infections are the next threat. It may therefore be best not to immunosuppress patients with a very poor renal prognosis who appear to be at low risk of pulmonary haemorrhage. Treatment can usually be curtailed after 3 months without recurrence. ANCA and anti-GBM antibodies occur together in some patients. This is typically an older group which often has features of vasculitis, and the anti-GBM response may often be secondary. Longer treatment as for small vessel vasculitis is usually indicated.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Cui, Zhao, Neil Turner, and Ming-hui Zhao. Alport post-transplant antiglomerular basement membrane disease. Edited by Neil Turner. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0075.

Повний текст джерела
Анотація:
Alport antiglomerular basement membrane (anti-GBM) disease is a rare example of disease caused by allo-sensitization after renal transplantation, first described in 1992. Because the recipient lacks a specific glomerular basement membrane (GBM) protein, they can become sensitized to the normal molecule present in the GBM of the donor kidney. The disease is restricted to the allograft. Interestingly severe disease arises from this only arises rarely, certainly less than 1 in 20, probably closer to 1 in 50. It characteristically causes late graft loss in a first transplant with accelerated tempo in later allografts, and in its most extreme form recurs within days. However, inexplicably some subsequent transplants do not provoke aggressive recurrence. Treatment of the most aggressive disease is difficult and in most cases has been ultimately unsuccessful. Lower levels of immune response, marked by linear binding of immunoglobulin-G to GBM without glomerular disease, are not uncommon in Alport patients after transplantation and should not lead to altered treatment. Immunoassays for anti-GBM antibodies can be misleading as in most cases the target of antibodies is the α‎‎‎5 chain of type IV collagen, rather than the α‎‎‎3 chain which is the target in spontaneous anti-GBM disease. Overall the outcome of transplantation in Alport syndrome is better than average. This complication is more likely in patients with partial or total gene deletion rather than point mutations, but no other predictive features have been identified.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Cattran, Daniel C., and Heather N. Reich. Membranous glomerulonephritis. Edited by Neil Turner. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0064_update_001.

Повний текст джерела
Анотація:
It has been clear for several decades from comparison with the rodent model disease Heymann nephritis that membranous glomerulonephritis (MGN) is an immune condition in which antibodies, usually autoantibodies, bind to targets on the surface of podocytes. However, the antigen in Heymann nephritis, megalin, is not present on human podocytes. The first potential antigen was identified by studying rare examples of maternal alloimmunization, leading to congenital membranous nephropathy in the infant caused by antibodies to neutral endopeptidase. More recently, the target of autoantibody formation in most patients with primary MGN has been identified to be the phospholipase A2 receptor, PLA2R. Genome-wide association studies identify predisposing genetic loci at HLADQ and at the locus encoding the autoantigen itself. So antibodies to at least two different molecular targets can cause MGN, and it seems likely that there may be other targets in secondary types of MGN, and possibly haptenized or otherwise modified molecules are implicated in drug- and toxin-induced MGN. Once antibodies are fixed, animal models and human observations suggest that complement is involved in mediating tissue damage. However, immunoglobulin G4, not thought to fix complement, is the predominant isotype in human MGN, and the mechanisms are not fully unravelled. Podocyte injury is known to cause proteinuria. In MGN, antibody fixation or cell damage may stimulate production of extracellular matrix to account for the increased GBM thickness with ‘podocyte type’ basement membrane collagen isoforms, and ultimately cell death and glomerulosclerosis.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Group, Diagram, and Group Diagram. Patience Card Games (Collins Gem). HarperCollins Publishers, 1996.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "GBM Patients"

1

Boiardi, A., A. Silvani, S. Valentini, A. Salmaggi, M. Botturi, M. Farinotti, and C. Giorgi. "Carboplatin combined with Carmustine and Etoposide in the treatment of glioblastoma (GBM) patients." In Cancer Treatment An Update, 604–6. Paris: Springer Paris, 1994. http://dx.doi.org/10.1007/978-2-8178-0765-2_128.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Gentilal, Nichal, Ricardo Salvador, and Pedro Cavaleiro Miranda. "A Thermal Study of Tumor-Treating Fields for Glioblastoma Therapy." In Brain and Human Body Modeling 2020, 37–62. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-45623-8_3.

Повний текст джерела
Анотація:
AbstractTumor-treating fields (TTFields) is an antimitotic cancer treatment technique used for glioblastoma multiforme (GBM) and malignant pleural mesothelioma. Although the frequency used is not as high as in hyperthermia, temperature increases due to the Joule effect might be meaningful given the necessary time that these fields should be applied for. Post hoc analysis of the EF-11 clinical trial showed higher median overall survival in patients whose compliance was at least 18 h per day. To quantify these temperature increases and predict the thermal impact of TTFields delivery to the head, we used a realistic model created from MR images segmented in five tissues: scalp, skull, CSF, gray matter (GM), and white matter (WM). Through COMSOL Multiphysics, we solved Laplace’s equation for the electric field and Pennes’ equation for the temperature distribution. To mimic the therapy as realistically as possible, we also considered complete current shutdown whenever any transducer reached 41 °C to allow transducers and tissues’ temperature to decrease. Our results indicate an intermittent operation of Optune due to this necessary current shutdown. Localized temperature increases were seen, especially underneath the regions where the transducers were placed. Maximum temperature values were around 41.5 °C on the scalp and 38 °C on the brain. According to the literature, significant thermal impact is only predicted for the brain where the rise in temperature may lead to an increased BBB permeability and variation in the blood flow and neurotransmitter concentration. Additionally, our results showed that if the injected current is reduced by around 25% compared to Optune’s standard way of operating, then uninterrupted treatment might be attainable. These predictions might be used to improve TTFields delivery in real patients and to increase awareness regarding possible thermal effects not yet reported elsewhere.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Eastlack, Steven, Cassandra Armstead-Williams, Christopher H. Bailey, Lexus Trosclair, Farees Hyatali, Shilpa Patil, Harish Siddaiah, et al. "Patient with Guillain Barre Syndrome (GBS)." In Guide to the Inpatient Pain Consult, 387–405. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-40449-9_26.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Tsang, Wai Kit, and Dries F. Benoit. "Interpretable GAM Models: Predicting Sepsis in ICU Patients." In Living Beyond Data, 101–29. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-11593-6_6.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Aleshchenkova, Viktoria. "DRG-Anreizwirkungen auf die medizinische Versorgung von Erwachsenen mit gMB." In Versorgung von Patienten mit geistiger und Mehrfachbehinderung, 30–82. Wiesbaden: Springer Fachmedien Wiesbaden, 2017. http://dx.doi.org/10.1007/978-3-658-19057-6_4.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Auberger, K., P. Kurnik, A. Flemmer, M. Praun, N. Nohe, and G. Frösner. "Prävalenz des GBV-C-Virus bei Patienten mit Gerinnungsstörungen." In 27. Hämophilie-Symposion Hamburg 1996, 33–38. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-80403-8_5.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

NíChonghaile, Mairéad. "Graft Versus Tumour Effect." In The European Blood and Marrow Transplantation Textbook for Nurses, 269–74. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-23394-4_13.

Повний текст джерела
Анотація:
AbstractThe treatment of relapsed disease remains challenging, and it is well accepted that concept of allogeneic HSCT relies upon both the conditioning or preparative regimen used for the recipient and the graft versus malignancy (GvM) or leukaemia (GvL) effect provided by the donor T cells and NK cells. Strategies which involve harnessing this effect are crucial to success and need to be exploited and refined to improve outcome. Further research is required to identify new strategies and therapies to improve the outlook for patients who relapse post-HSCT.The nursing challenges following relapse are immense; the psychological support required is complex and largely falls to the nurse to coordinate and deliver regardless of the selected treatment approach.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Gentilal, Nichal, Ariel Naveh, Tal Marciano, Zeev Bomzon, Yevgeniy Telepinsky, Yoram Wasserman, and Pedro Cavaleiro Miranda. "The Impact of Scalp’s Temperature in the Predicted LMiPD in the Tumor During TTFields Treatment for Glioblastoma Multiforme." In Brain and Human Body Modelling 2021, 3–18. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-15451-5_1.

Повний текст джерела
Анотація:
AbstractTumor Treating Fields (TTFields) is a cancer treatment technique used for glioblastoma multiforme (GBM). It consists in the application of an electric field (EF) in two perpendicular directions alternately by placing transducer arrays on the patient’s scalp. In-vitro studies showed that the higher the electric field in the tumor, the better are the outcomes of the therapy. Therefore, these arrays are strategically placed in positions that can optimize the EF, based on the results of computational simulations. However, due to the required daily usage of this technique, at least 18 hours per day, the temperature of head tissues increases inevitably. To ensure patient’s safety, the temperature of the scalp is monitored and kept around 39.5 °C by changing the injected current, which consequently changes the EF in the tumor. In this work, we studied the impact that accounting for the temperature of the scalp might have in the choice of which layout should be used during TTFields planning. We used both a simplified and a realistic head model in our studies. We solved Laplace’s equation for the electric potential and Pennes’ equation for the temperature distribution using COMSOL Multiphysics. The electric field in the tumor was evaluated using the local minimum power density (LMiPD) both when the temperature of the scalp was considered in treatment planning and when it was not. We concluded that the values of the LMiPD significantly decrease when the temperature is considered. Furthermore, layouts in which two pairs of different arrays are very close to each other lead to the appearance of a common temperature hotspot, and consequently to the most significant variations in the predicted LMiPD values. In future, TTFields treatment planning studies, considering the temperature of the scalp might be beneficial to improve the predictions of treatment effectiveness.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Rudzite, V., J. Berzinsh, I. Grivane, D. Fuchs, G. Baier-Bitterlich, and H. Wachter. "Serum Tryptophan, Kynurenine, and Neopterin in Patients with Guillain-Barre-Syndrome (GBS) and Multiple Sclerosis (MS)." In Advances in Experimental Medicine and Biology, 183–87. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4613-0381-7_30.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Miller, Gabriel F., Juan Camilo Vásquez-Correa, and Elmar Nöth. "Assessing the Dysarthria Level of Parkinson’s Disease Patients with GMM-UBM Supervectors Using Phonological Posteriors and Diadochokinetic Exercises." In Text, Speech, and Dialogue, 356–65. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-58323-1_39.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "GBM Patients"

1

Droz, N., A. Katz, J. Sedor, and R. Hajj-Ali. "AB0687 Does anti-glomerular basement membrane (ANTI-GBM) antibody positivity correlate with relapse in patients with anti-gbm disease?" In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.1671.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Wangaryattawanich, Pattana, Jixin Wang, Ginu A. Thomas, Ahmad Chaddad, Pascal O. Zinn, and Rivka R. Colen. "Survival analysis of pre-operative GBM patients by using quantitative image features." In 2014 International Conference on Control, Decision and Information Technologies (CoDIT). IEEE, 2014. http://dx.doi.org/10.1109/codit.2014.6996968.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Teixeira, Hennan Salzedas, Murillo Silva Catito, Adrialdo José Santos, Gabriel Novaes de Rezende Batistella, Andreia Martini Pazini, and Thays Neri Andrade. "Giant cell glioblastoma: a case report of a long-term survival." In XIV Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2023. http://dx.doi.org/10.5327/1516-3180.141s1.670.

Повний текст джерела
Анотація:
Glioblastoma (GBM) is the most common primary brain tumor in adults, classified as grade 4 by World Health Organization, with a mean overall survival of 15–18 months. The histopathological subtype described as giant cell GBM corresponds to < 1% of this tumor, more frequent in young patients, affecting the temporal and parietal lobes in a more circumscribed and subcortical way. We present a case report of a woman diagnosed with GBM giant cell (GC). Data was collected through electronic medical record. A 19-years-old woman, healthy, during investigation of headache with visual and speech alteration, a cranial tomography was performed in January 2009, demonstrating a supratentorial lesion. Cranial magnetic resonance imaging showed a solid-cystic, infiltrative lesion with perilesional edema, located in the left parietal region and heterogeneous peripheral enhancement. Subtotal resection of the lesion was performed in February 2010. The anatomopathological study was compatible with GC, and adjuvant treatment was performed with radiotherapy (60 Gy, in 30 fractions) and concomitant chemotherapy, temozolamide (TMZ), followed by adjuvant TMZ, monthly for seven cycles. The patient developed osteomyelitis and it was necessary to suspend the adjuvant chemotherapy in November 2010. Clinical and radiological follow-up showed stability of the lesion and staying functionally independent, with progression-free survival >13 years. This is an atypical case of a patient with glioblastoma with prolonged survival. Some studies suggest that the dominant presence of giant cells, extent of surgical resection in addition to some molecular may be predictors of long-term survival. Besides the rarity of this malignancy and heterogeneity response with the treatment, it’s important to recognize this subtype of GBM and to treat aggressively for the possible of achieve better outcomes, until better therapeutic data are available.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Ahmed, Kaoutar Ben, Lawrence O. Hall, Renhao Liu, Robert A. Gatenby, and Dmitry B. Goldgof. "Neuroimaging Based Survival Time Prediction of GBM Patients Using CNNs from Small Data." In 2019 IEEE International Conference on Systems, Man and Cybernetics (SMC). IEEE, 2019. http://dx.doi.org/10.1109/smc.2019.8913929.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Reardon, David A., Thomas Kaley, Jorg Dietrich, Michael Lim, Gavin P. Dunn, Hui K. Gan, Timothy Cloughesy, et al. "Abstract IA20: Phase II study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM): Results for cohort B (durvalumab monotherapy), bevacizumab-naïve patients with recurrent GBM." In Abstracts: Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 25-28, 2016; New York, NY. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/2326-6066.imm2016-ia20.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Castro, Natasha Kuromoto de, Luisa Oliveira Wey Rossettini, and Mirto Nelso Prandini. "The future in glioblastoma treatment." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.081.

Повний текст джерела
Анотація:
Introduction: Glioblastoma multiforme (GBM) is the most aggressive tumor that affects humans. Surgical treatment based on cytoreduction presents serious limitations. Consequently, treatments that use selective measures, in order to define relevant antigens that retard growth and recurrences, acquire a prominent position. The complex tumor microenvironment and the infiltration into adjacent tissues make surgical therapies, radiotherapy and chemotherapy, approaches still unsatisfactory when the increase in survival rate is evaluated. Studies on central nervous system immunovigilance have found the presence of lymphatic vessels and the perivascular system that allows the presentation of antigens to T4 cells bringing with it great relevance of immunotherapy, and the creation of active immune responses, recruiting the immune system itself to fight the tumor locally or systemically. Objectives: Determine the effectiveness of combining immunotherapy with conventional therapies of treatments in order to prolong the survival of patients with GBM. Methodology: Databases of Springer Link, Oxford academic, PubMed, Biblioteca USP. Results: For an active immunotherapy to be well-defined, it is necessary to have a strong and efficient antigen presentation breaking the state of tumor immune tolerance and activating effector lymphocytes. The use of dendritic cells for this presentation may be a good strategy. Finally, the antitumor response requires coordination between various local and systemic components. Conclusion: The use of immunotherapy in the treatment of GBM continues to expand. Despite several problems, due to immunosuppression mediated by the tumor itself, the immunotherapy brings a hope regarding to the possibility of to increase the immunogenicity and, thus, prolonging patient survival.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Castle, John, Dan Levey, Elise Drouin, Nicholas Wilson, Steven Schoenfeld, Orin Bloch, and Jennifer Buell. "Abstract A109: Exploring neo-antigens and immunological response in GBM patients after individualized Prophage vaccination." In Abstracts: CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr15-a109.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Skog, Johan, Stefan Bentink, Lori LoGuidice, Charlotte Romain, Susan Belzer, and Mikkel Noerholm. "Abstract LB-108: Exosome profiling of mRNAs and miRNAs in serum samples from GBM patients ." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-lb-108.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Gonçalves, Paola Gyuliane. "Analysis of the potential prognostic of ELAVL2, FOCAD and MLLT3 in glioblastoma." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.363.

Повний текст джерела
Анотація:
Background: There is a crucial demand to identify molecular markers for cancer to improve the personalized treatment, diagnosis and prognosis. Our research group described a frequently deleted region (chr9p22.1-p21.3) in gliomas, with genes potentially important in the development of this tumor type, including ELAVL2, FOCAD and MLLT3. Objectives: Therefore, the aim of this study was to analyze the expression of those genes as potential biomarkers for glioblastoma (GBM) prognosis. Design and setting: The study was retrospective with samples collected at Barretos Cancer Hospital. Methods: Immunohistochemistry reactions were performed for ELAVL2, FOCAD and MLLT3 proteins in 83 GBM samples. The reactions were evaluated using scores of intensity and extension, ranging from 0 to 6 in total. Patients with expression scores between 0 and 2 were considered negative for the expression of the specific gene, and those with scores between 3 and 6 were considered positive. Clinicopathological and molecular data from patients (age, gender, tumor location, KPS, and overall survival) were correlated with the expression of each gene. Results: ELAVL2-expressing tumors showed a trend to develop in the temporal lobe (P=0.052), whereas they were not found in the frontal lobe. Patients with FOCAD expression were older (>45y.o., p<0.001). Overall survival was not influenced by ELAVL2 or FOCAD expression. Patients with MLLT3 expression presented a marginal improved overall survival (p=0.077) when compared with patients without expression. Conclusion: Although there was a correlation of ELAVL2 and FOCAD with tumor location and age, respectively, these genes did not show prognostic potential in glioblastomas. MLLT3 showed potential prognostic, albeit more studies are warranted with larger cohorts.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Das, Tapojyoti, Uttara Chatterjee, Samarendra Nath Ghosh, Sumit Deb, Suniti Kumar Saha, Puneet Gulati, Sarang Rote, Vikas Chandra, Ankur Mukherjee, and Surajit Dhara. "Abstract 5587: An objective clustering of GBM patients to identify clinically relevant subgroup with Hedgehog pathway activity." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-5587.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "GBM Patients"

1

Williams, Reg A. Stress Gym for Combat Casualty Patients. Fort Belvoir, VA: Defense Technical Information Center, August 2011. http://dx.doi.org/10.21236/ada624620.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Sri Sailaja Rani, M., Dr Pasula Anurag, and Dr K. Swapnika Lahari. ROLE OF GUM CHEWING ON THE DURATION OF POSTOPERATIVE ILEUS FOLLOWING ABDOMINAL SURGERIES. World Wide Journals, February 2023. http://dx.doi.org/10.36106/ijar/3106430.

Повний текст джерела
Анотація:
AIMS & OBJECTIVES:1) To evaluate the effect of gum chewing on the duration of postoperative ileus following abdominal surgeries. Patients in study group (n=25) were asked to chew one stick of METHODS: chewing gum for 30 min four times a day until passing atus while the control group (n=25) patients were kept nil per orally until the passage of atus. RESULTS: Based on the results it can be concluded that on chewing gum it was seen that the duration of overall recovery of bowel movements in form of appearance of bowel sound, passing atus and motion and feeling of hunger, occurred early in patients chewing gum CONCLUSION:Gum chewing after abdominal surgeries has shown to signicantly reduced postoperative ileus as judged by the appearance of bowelsounds ansd passage of atus as well as stools.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Weng, JIeqiong, Jingfang Zhang, Ke Xu, Mengfei Yuan, Tingting Yao, Xinyu Wang, and Xiaoxu Shen. Efficacy of Shexiang Baoxin Pills Combined with Statins on Blood Lipid Profile in Patients with Coronary Heart Disease: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0100.

Повний текст джерела
Анотація:
Review question / Objective: P（Population) ：Patients with coronary heart disease; I（Intervention) : Statins treatment in combination with Shexiang Baoxin pill; C（Comparison): Statins alone; O（Outcome）: Improvement of symptoms and blood lipids; S（Study design）：Clinical randomized trials. Eligibility criteria: To be included, trials were required to meet the following criteria: (1) patients were included in the studies according to diagnostic criteria of coronary heart disease established by the WHO, InternationalSociety of Cardiology and Association (ISCA), Internal Medicine, 7th edition ( IM-7th), Practice of InternalMedicine, 14th edition ( PIM-14th), Guidelines for the Diagnosis of Cardiovascular Diseases in InternalMedicine, 3rd edition (GIM-3rd) or conventional diagnostic criteria (CDC) including assessment of anginapectoris and electrocardiogram (ECG) results; (2) the study was conducted as a randomized controlled trial.
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "GBM Patients" для конкретних типів джерел:
Статті в журналах Дисертації Книги
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії